The treatment of Castration-resistant prostate cancer (CRPC) cells with the AVPR1A ligand, arginine vasopressin (AVP), activated cAMP response element-binding protein (CREB) via the RAS-MAPK transduction cascade (Zhao et al., 2019). This evidence concerns the gene AVP and prostate carcinoma.